Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1418-1429

  Skeate, Joseph G ^a   Woodham, Andrew W ^a   Einstein, Mark H ^b   Da Silva, Diane M ^a,c   Kast, W Martin ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

anogenital cancers; cervical cancer; checkpoint inhibitors; head and neck cancer; human papillomavirus; immunotherapy; therapeutic vaccines

Indexed keywords

CALRETICULIN; CAPSID PROTEIN; DNA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; VIRUS VECTOR; WART VIRUS VACCINE;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; CELL PROLIFERATION; CELL THERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; ELECTROPORATION; FEMALE GENITAL TRACT CANCER; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHENOTYPE; REVIEW; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS REPLICATION; CLINICAL TRIAL (TOPIC); PAPILLOMAVIRUS INFECTIONS; PRECLINICAL STUDY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84962124071     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1136039     Document Type: Review

References (147)

1. E.F.Dunne, E.R.Unger, M.Sternberg, G.McQuillan, D.C.Swan, S.S.Patel, L.E.Markowitz. Prevalence of HPV infection among females in the United States. Jama-J Am Med Assoc 2007; 297:813-9; http://dx.doi.org/10.1001/jama.297.8.813
2. L.Koutsky. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8; PMID:9217656; http://dx.doi.org/10.1016/S0002-9343(97)00177-0
3. C.L.Satterwhite, E.Torrone, E.Meites, E.F.Dunne, R.Mahajan, M.C.Ocfemia, J.Su, F.Xu, H.Weinstock. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40:187-93; PMID:23403598; http://dx.doi.org/10.1097/OLQ.0b013e318286bb53
4. E.L.Franco, L.L.Villa, J.P.Sobrinho, J.M.Prado, M.C.Rousseau, M.Desy, T.E.Rohan. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180:1415-23; PMID:10515798; http://dx.doi.org/10.1086/315086
5. G.Y.Ho, R.D.Burk, S.Klein, A.S.Kadish, C.J.Chang, P.Palan, J.Basu, R.Tachezy, R.Lewis, S.Romney. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87:1365-71; PMID:7658497; http://dx.doi.org/10.1093/jnci/87.18.1365
6. A.B.Moscicki. Impact of HPV infection in adolescent populations. J Adolesc Health 2005; 37:S3-9; PMID:16310138; http://dx.doi.org/10.1016/j.jadohealth.2005.09.011
7. J.M.Walboomers, M.V.Jacobs, M.M.Manos, F.X.Bosch, J.A.Kummer, K.V.Shah, P.J.Snijders, J.Peto, C.J.Meijer, N.Munoz. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH431%3e3.0.CO;2-F
8. F.X.Bosch, M.M.Manos, N.Munoz, M.Sherman, A.M.Jansen, J.Peto, M.H.Schiffman, V.Moreno, R.Kurman, K.V.Shah. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802; PMID:7791229; http://dx.doi.org/10.1093/jnci/87.11.796
9. R.Ghittoni, R.Accardi, S.Chiocca, M.Tommasino. Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience 2015; 9:526; PMID:25987895; http://dx.doi.org/10.3332/ecancer.2015.526
10. D.Forman, C.de Martel, C.J.Lacey, I.Soerjomataram, J.Lortet-Tieulent, L.Bruni, J.Vignat, J.Ferlay, F.Bray, M.Plummer, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 Suppl 5:F12-23; PMID:23199955; http://dx.doi.org/10.1016/j.vaccine.2012.07.055
11. J.S.I.Ferlay, M.Ervik, R.Dikshit, S.Esser, C.Mathers, M.Rebelo, D.M.Parkin, D.Forman, F.Bray. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013, 2013.
12. M.Watson, M.Saraiya, V.Benard, S.S.Coughlin, L.Flowers, V.Cokkinides, M.Schwenn, Y.Huang, A.Giuliano. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008; 113:2855-64; PMID:18980204; http://dx.doi.org/10.1002/cncr.23756
13. J.S.Smith. Ethnic disparities in cervical cancer illness burden and subsequent care: a prospective view in managed care. The American journal of managed care 2008; 14:S193-9; PMID:18611087
14. H.Mehanna, T.Beech, T.Nicholson, I.El-Hariry, C.McConkey, V.Paleri, S.Roberts. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer–systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35:747-55; PMID:22267298; http://dx.doi.org/10.1002/hed.22015
15. C.C.Ragin, E.Taioli. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121:1813-20; PMID:17546592; http://dx.doi.org/10.1002/ijc.22851
16. A.K.Chaturvedi, E.A.Engels, R.M.Pfeiffer, B.Y.Hernandez, W.Xiao, E.Kim, B.Jiang, M.T.Goodman, M.Sibug-Saber, W.Cozen, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301; PMID:21969503; http://dx.doi.org/10.1200/JCO.2011.36.4596
17. N.Ganguly, S.P.Parihar. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 2009; 34:113-23; PMID:19430123; http://dx.doi.org/10.1007/s12038-009-0013-7
18. C.B.Buck, C.D.Thompson, Y.Y.Pang, D.R.Lowy, J.T.Schiller. Maturation of papillomavirus capsids. J Virol 2005; 79:2839-46; PMID:15709003; http://dx.doi.org/10.1128/JVI.79.5.2839-2846.2005
19. N.Hafner, C.Driesch, M.Gajda, L.Jansen, R.Kirchmayr, I.B.Runnebaum, M.Durst. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008; 27:1610-7; PMID:17828299; http://dx.doi.org/10.1038/sj.onc.1210791
20. H.zur Hausen. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50; PMID:12044010; http://dx.doi.org/10.1038/nrc798
21. Group TFIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
22. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morbidity and mortality weekly report 2010; 59:630-2; PMID:20508594
23. T.Kirby. FDA approves new upgraded Gardasil 9. The Lancet Oncology 2015; 16:e56; PMID:25532625; http://dx.doi.org/10.1016/S1470-2045(14)71191-X
24. E.A.Joura, A.R.Giuliano, O.E.Iversen, C.Bouchard, C.Mao, J.Mehlsen, E.D.Moreira, Jr., Y.Ngan, L.K.Petersen, E.Lazcano-Ponce, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044
25. S.Stokley, J.Jeyarajah, D.Yankey, M.Cano, J.Gee, J.Roark, R.C.Curtis, L.Markowitz. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morbidity and mortality weekly report 2014; 63:620-4; PMID:25055185
26. S.Reagan-Steiner, D.Yankey, J.Jeyarajah, L.D.Elam-Evans, J.A.Singleton, C.R.Curtis, J.MacNeil, L.E.Markowitz, S.Stokley. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years–United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:784-92; PMID:26225476; http://dx.doi.org/10.15585/mmwr.mm6429a3
27. D.Saslow, D.Solomon, H.W.Lawson, M.Killackey, S.L.Kulasingam, J.Cain, F.A.Garcia, A.T.Moriarty, A.G.Waxman, D.C.Wilbur, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137:516-42; PMID:22431528; http://dx.doi.org/10.1309/AJCPTGD94EVRSJCG
28. Administration USFaD. FDA approves first human papillomavirus test for primary cervical cancer screening. 2014.
29. M.H.Stoler, T.C.Wright, Jr., A.Sharma, R.Apple, K.Gutekunst, T.L.Wright, Group AHS. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135:468-75; PMID:21350104; http://dx.doi.org/10.1309/AJCPZ5JY6FCVNMOT
30. T.C.Wright, Jr., M.H.Stoler, A.Sharma, G.Zhang, C.Behrens, T.L.Wright. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. American journal of clinical pathology 2011; 136:578-86; PMID:21917680; http://dx.doi.org/10.1309/AJCPTUS5EXAS6DKZ
31. M.R.Schmiedeskamp, D.R.Kockler. Human papillomavirus vaccines. Ann Pharmacother 2006; 40:1344-52; PMID:16849621; http://dx.doi.org/10.1345/aph.1G723
32. R.Kirnbauer, F.Booy, N.Cheng, D.R.Lowy, J.T.Schiller. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89:12180-4; PMID:1334560; http://dx.doi.org/10.1073/pnas.89.24.12180
33. M.Stanley. Immune responses to human papillomavirus. Vaccine 2006; 24 Suppl 1:S16-22; PMID:16219398; http://dx.doi.org/10.1016/j.vaccine.2005.09.002
34. Centers for Disease C, Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morbidity and mortality weekly report 2011; 60:1705-8; PMID:22189893
35. L.E.Markowitz, E.F.Dunne, M.Saraiya, H.W.Lawson, H.Chesson, E.R.Unger, Centers for Disease C, Prevention, Advisory Committee on Immunization P. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24; PMID:17380109
36. E.Barr, G.Tamms. Quadrivalent human papillomavirus vaccine. Clin Infect Dis 2007; 45:609-7; PMID:17682997; http://dx.doi.org/10.1086/520654
37. D.M.Harper, E.L.Franco, C.M.Wheeler, A.B.Moscicki, B.Romanowski, C.M.Roteli-Martins, D.Jenkins, A.Schuind, S.A.Costa Clemens, G.Dubin, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55; PMID:16631880; http://dx.doi.org/10.1016/S0140-6736(06)68439-0
38. K.A.Ault, Group FIS. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369:1861-8; PMID:17544766; http://dx.doi.org/10.1016/S0140-6736(07)60852-6
39. N.Kajitani, A.Satsuka, A.Kawate, H.Sakai. Productive Lifecycle of Human Papillomaviruses that Depends Upon Squamous Epithelial Differentiation. Front Microbiol 2012; 3:152; PMID:22536200; http://dx.doi.org/10.3389/fmicb.2012.00152
40. J.B.Hudson, M.A.Bedell, D.J.McCance, L.A.Laiminis. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990; 64:519-26; PMID:2153221
41. S.Tan, E.G.de Vries, A.G.van der Zee, S.de Jong. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 2012; 12:170-84; PMID:22165971; http://dx.doi.org/10.2174/156800912799095135
42. N.Ganguly. Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value. Cell Oncol (Dordr) 2012; 35:67-76; PMID:22262402; http://dx.doi.org/10.1007/s13402-011-0069-x
43. M.A.Steller, K.J.Gurski, M.Murakami, R.W.Daniel, K.V.Shah, E.Celis, A.Sette, E.L.Trimble, R.C.Park, F.M.Marincola. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4:2103-9; PMID:9748126
44. W.M.Kast, R.M.Brandt, J.Sidney, J.W.Drijfhout, R.T.Kubo, H.M.Grey, C.J.Melief, A.Sette. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152:3904-12; PMID:7511661
45. E.J.Davidson, R.L.Faulkner, P.Sehr, M.Pawlita, L.J.Smyth, D.J.Burt, A.E.Tomlinson, J.Hickling, H.C.Kitchener, P.L.Stern. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004; 22:2722-9; PMID:15246603; http://dx.doi.org/10.1016/j.vaccine.2004.01.049
46. I.H.Frazer, M.Quinn, J.L.Nicklin, J.Tan, L.C.Perrin, P.Ng, V.M.O'Connor, O.White, N.Wendt, J.Martin, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23:172-81; PMID:15531034; http://dx.doi.org/10.1016/j.vaccine.2004.05.013
47. M.H.Einstein, A.S.Kadish, R.D.Burk, M.Y.Kim, S.Wadler, H.Streicher, G.L.Goldberg, C.D.Runowicz. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106:453-60; PMID:17586030; http://dx.doi.org/10.1016/j.ygyno.2007.04.038
48. A.de Jong, T.O'Neill, A.Y.Khan, K.M.Kwappenberg, S.E.Chisholm, N.R.Whittle, J.A.Dobson, L.C.Jack, J.A.St Clair Roberts, R.Offringa, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002; 20:3456-64; PMID:12297390; http://dx.doi.org/10.1016/S0264-410X(02)00350-X
49. J.A.Brinkman, S.H.Hughes, P.Stone, A.S.Caffrey, L.I.Muderspach, L.D.Roman, J.S.Weber, W.M.Kast. Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007; 23:337-52; PMID:17627067; http://dx.doi.org/10.1155/2007/245146
50. P.Berraondo, C.Nouze, X.Preville, D.Ladant, C.Leclerc. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Research 2007; 67:8847-55; PMID:17875726; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321
51. C.M.Zhou, G.X.Zhang, X.X.Ma. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein. J Virol Methods 2014; 197:1-6; PMID:24291739; http://dx.doi.org/10.1016/j.jviromet.2013.10.033
52. H.Khallouf, A.K.Grabowska, A.B.Riemer. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) 2014; 2:422-62; PMID:26344626; http://dx.doi.org/10.3390/vaccines2020422
53. S.Jang, Y.T.Kim, H.W.Chung, K.R.Lee, J.B.Lim, K.Lee. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer. Cancer 2012; 118:2173-83; PMID:21918960; http://dx.doi.org/10.1002/cncr.26468
54. S.Kim, H.W.Chung, K.R.Lee, J.B.Lim. Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer. J Transl Med 2014; 12:229; PMID:25141788; http://dx.doi.org/10.1186/s12967-014-0229-7
55. G.G.Kenter, M.J.Welters, A.R.Valentijn, M.J.Lowik, D.M.Berends-van der Meer, A.P.Vloon, J.W.Drijfhout, A.R.Wafelman, J.Oostendorp, G.J.Fleuren, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14:169-77; PMID:18172268; http://dx.doi.org/10.1158/1078-0432.CCR-07-1881
56. M.P.Rudolf, S.Man, C.J.Melief, A.Sette, W.M.Kast. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001; 7:788s-95s; PMID:11300474
57. A.M.Solares, I.Baladron, T.Ramos, C.Valenzuela, Z.Borbon, S.Fanjull, L.Gonzalez, D.Castillo, J.Esmir, M.Granadillo, et al. Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol 2011; 2011:292951; PMID:21748025; http://dx.doi.org/10.5402/2011/292951
58. L.Muderspach, S.Wilczynski, L.Roman, L.Bade, J.Felix, L.A.Small, W.M.Kast, G.Fascio, V.Marty, J.Weber. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6:3406-16; PMID:10999722
59. W.J.van Driel, M.E.Ressing, G.G.Kenter, R.M.Brandt, E.J.Krul, A.B.van Rossum, E.Schuuring, R.Offringa, T.Bauknecht, A.Tamm-Hermelink, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35:946-52; PMID:10533477; http://dx.doi.org/10.1016/S0959-8049(99)00048-9
60. G.G.Kenter, M.J.Welters, A.R.Valentijn, M.J.Lowik, D.M.Berends-van der Meer, A.P.Vloon, F.Essahsah, L.M.Fathers, R.Offringa, J.W.Drijfhout, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx.doi.org/10.1056/NEJMoa0810097
61. C.W.Wu, J; Hwang, K. Preclinical Efficacy and Safety Studies of PEK Fusion Protein in GPI-0100 Adjuvant for HPV-infectious Disease Immnotherapy. HPV 2015 - Lisbon 2015.
62. Y.Paterson, P.C.Maciag. Listeria-based vaccines for cancer treatment. Curr Opin Mol Ther 2005; 7:454-60; PMID:16248280
63. H.A.Carleton. Pathogenic bacteria as vaccine vectors: teaching old bugs new tricks. Yale J Biol Med 2010; 83:217-22; PMID:21165341
64. D.van Duin, R.Medzhitov, A.C.Shaw. Triggering TLR signaling in vaccination. Trends Immunol 2006; 27:49-55; PMID:16310411; http://dx.doi.org/10.1016/j.it.2005.11.005
65. G.Trinchieri, A.Sher. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179-90; PMID:17318230; http://dx.doi.org/10.1038/nri2038
66. J.L.Brandsma, M.Shlyankevich, L.Zhang, M.D.Slade, E.C.Goodwin, W.Peh, A.B.Deisseroth. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol 2004; 78:116-23; PMID:14671093; http://dx.doi.org/10.1128/JVI.78.1.116-123.2004
67. L.K.Borysiewicz, A.Fiander, M.Nimako, S.Man, G.W.Wilkinson, D.Westmoreland, A.S.Evans, M.Adams, S.N.Stacey, M.E.Boursnell, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-7; PMID:8684105; http://dx.doi.org/10.1016/S0140-6736(96)90674-1
68. J.L.Brun, V.Dalstein, J.Leveque, P.Mathevet, P.Raulic, J.J.Baldauf, S.Scholl, B.Huynh, S.Douvier, D.Riethmuller, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011; 204:169 e1-8; PMID:21284968; http://dx.doi.org/10.1016/j.ajog.2010.09.020
69. J.G.Gomez-Gutierrez, K.G.Elpek, R.Montes de Oca-Luna, H.Shirwan, H.Sam Zhou, K.M.McMasters. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007; 56:997-1007; PMID:17146630; http://dx.doi.org/10.1007/s00262-006-0247-2
70. R.B.Roden, M.Ling, T.C.Wu. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004; 35:971-82; PMID:15297964; http://dx.doi.org/10.1016/j.humpath.2004.04.007
71. K.P.Nishimoto, A.K.Laust, K.Wang, K.I.Kamrud, B.Hubby, J.F.Smith, E.L.Nelson. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol 2007; 20:88-104; PMID:17425424; http://dx.doi.org/10.1089/vim.2006.0090
72. T.Daemen, A.Riezebos-Brilman, J.Regts, B.Dontje, A.van der Zee, J.Wilschut. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004; 9:733-42; PMID:15535411
73. A.Riezebos-Brilman, J.Regts, E.J.Freyschmidt, B.Dontje, J.Wilschut, T.Daemen. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene therapy 2005; 12:1410-4; PMID:15843807; http://dx.doi.org/10.1038/sj.gt.3302536
74. M.C.Cassetti, S.P.McElhiney, V.Shahabi, J.K.Pullen, I.C.Le Poole, G.L.Eiben, L.R.Smith, W.M.Kast. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004; 22:520-7; PMID:14670335; http://dx.doi.org/10.1016/j.vaccine.2003.07.003
75. S.Song, M.Han, H.Zhang, Y.Wang, H.Jiang. Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing. Cell Mol Immunol 2013; 10:490-6; PMID:23954948; http://dx.doi.org/10.1038/cmi.2013.33
76. M.Moniz, M.Ling, C.F.Hung, T.C.Wu. HPV DNA vaccines. Frontiers in bioscience: a journal and virtual library 2003; 8:d55-68; PMID:12456324; http://dx.doi.org/10.2741/936
77. P.Ohlschlager, M.Pes, W.Osen, M.Durst, A.Schneider, L.Gissmann, A.M.Kaufmann. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006; 24:2880-93; PMID:16472545; http://dx.doi.org/10.1016/j.vaccine.2005.12.061
78. J.A.Brinkman, X.Xu, W.M.Kast. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 2007; 25:3437-44; PMID:17241713; http://dx.doi.org/10.1016/j.vaccine.2006.12.045
79. S.Peng, H.Ji, C.Trimble, L.He, Y.C.Tsai, J.Yeatermeyer, D.A.Boyd, C.F.Hung, T.C.Wu. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004; 78:8468-76; PMID:15280455; http://dx.doi.org/10.1128/JVI.78.16.8468-8476.2004
80. C.L.Trimble, S.Peng, F.Kos, P.Gravitt, R.Viscidi, E.Sugar, D.Pardoll, T.C.Wu. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7; PMID:19118066; http://dx.doi.org/10.1158/1078-0432.CCR-08-1725
81. F.Garcia, K.U.Petry, L.Muderspach, M.A.Gold, P.Braly, C.P.Crum, M.Magill, M.Silverman, R.G.Urban, M.L.Hedley, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103:317-26; PMID:14754702; http://dx.doi.org/10.1097/01.AOG.0000110246.93627.17
82. M.L.Bagarazzi, J.Yan, M.P.Morrow, X.Shen, R.L.Parker, J.C.Lee, M.Giffear, P.Pankhong, A.S.Khan, K.E.Broderick, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155ra38; http://dx.doi.org/10.1126/scitranslmed.3004414
83. T.J.Kim, H.T.Jin, S.Y.Hur, H.G.Yang, Y.B.Seo, S.R.Hong, C.W.Lee, S.Kim, J.W.Woo, K.S.Park, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 2014; 5:5317; PMID:25354725; http://dx.doi.org/10.1038/ncomms6317
84. C.L.Trimble, M.P.Morrow, K.A.Kraynyak, X.Shen, M.Dallas, J.Yan, L.Edwards, R.L.Parker, L.Denny, M.Giffear, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015; 386:2078-88; PMID:26386540; http://dx.doi.org/10.1016/S0140-6736(15)00239-1
85. B.Yang, A.Yang, S.Peng, X.Pang, R.B.Roden, T.C.Wu, C.F.Hung. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci 2015; 5:35; PMID:26113972; http://dx.doi.org/10.1186/s13578-015-0025-y
86. K.Palucka, J.Banchereau. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
87. A.Ferrara, M.Nonn, P.Sehr, C.Schreckenberger, M.Pawlita, M.Durst, A.Schneider, A.M.Kaufmann. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129:521-30; PMID:12898233; http://dx.doi.org/10.1007/s00432-003-0463-5
88. A.D.Santin, S.Bellone, M.Palmieri, A.Ravaggi, C.Romani, R.Tassi, J.J.Roman, A.Burnett, S.Pecorelli, M.J.Cannon. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006; 100:469-78; PMID:16249018; http://dx.doi.org/10.1016/j.ygyno.2005.09.040
89. T.H.Kang, J.H.Lee, H.C.Bae, K.H.Noh, J.H.Kim, C.K.Song, B.C.Shin, C.F.Hung, T.C.Wu, J.S.Park, et al. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 2006; 106:126-34; PMID:16844231; http://dx.doi.org/10.1016/j.imlet.2006.05.004
90. B.W.Tillman, T.L.Hayes, T.D.DeGruijl, J.T.Douglas, D.T.Curiel. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Research 2000; 60:5456-63; PMID:11034088
91. Z.X.Zhou, D.Li, S.S.Guan, C.Zhao, Z.L.Li, Y.Zeng. Immunotherapeutic Effects of Dendritic Cells Pulsed with a Coden-optimized HPV 16 E6 and E7 Fusion Gene in Vivo and in Vitro. Asian Pac J Cancer Prev 2015; 16:3843-7; PMID:25987047; http://dx.doi.org/10.7314/APJCP.2015.16.9.3843
92. R.Houot, L.M.Schultz, A.Marabelle, H.Kohrt. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. Cancer Immunol Res 2015; 3:1115-22; PMID:26438444; http://dx.doi.org/10.1158/2326-6066.CIR-15-0190
93. S.Stevanovic, L.M.Draper, M.M.Langhan, T.E.Campbell, M.L.Kwong, J.R.Wunderlich, M.E.Dudley, J.C.Yang, R.M.Sherry, U.S.Kammula, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015; 33:1543-50; PMID:25823737; http://dx.doi.org/10.1200/JCO.2014.58.9093
94. K.B.Scholten, M.W.Schreurs, J.J.Ruizendaal, E.W.Kueter, D.Kramer, S.Veenbergen, C.J.Meijer, E.Hooijberg. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clinical Immunology 2005; 114:119-29; PMID:15639645; http://dx.doi.org/10.1016/j.clim.2004.11.005
95. L.M.Draper, M.L.Kwong, A.Gros, S.Stevanovic, E.Tran, S.Kerkar, M.Raffeld, S.A.Rosenberg, C.S.Hinrichs. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res 2015; 21:4431-9; PMID:26429982; http://dx.doi.org/10.1158/1078-0432.CCR-14-3341
96. J.C.Luxton, A.J.Rowe, J.C.Cridland, T.Coletart, P.Wilson, P.S.Shepherd. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 1996; 77 (Pt 7):1585-93; PMID:8758003; http://dx.doi.org/10.1099/0022-1317-77-7-1585
97. M.H.Einstein, A.S.Kadish, R.D.Burk, M.Y.Kim, S.Wadler, H.Streicher, G.L.Goldberg, C.D.Runowicz. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106:453-60; PMID:17586030; http://dx.doi.org/10.1016/j.ygyno.2007.04.038
98. R.G.Petit, A.Mehta, M.Jain, S.Gupta, R.Nagarkar, V.Kumar, S.Premkumar, R.Neve, S.John, P.Basu. ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer. Journal for ImmunoTherapy of Cancer 2014; 2 (Suppl 3):92; http://dx.doi.org/10.1186/2051-1426-2-S3-P92
99. N.M.Berezhnaya. Interaction between tumor and immune system: the role of tumor cell biology. Exp Oncol 2010; 32:159-66; PMID:21403611
100. A.H.Sharpe, G.J.Freeman. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri727
101. Y.Agata, A.Kawasaki, H.Nishimura, Y.Ishida, T.Tsubata, H.Yagita, T.Honjo. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-72; PMID:8671665; http://dx.doi.org/10.1093/intimm/8.5.765
102. M.K.Callahan, M.A.Postow, J.D.Wolchok. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol 2014; 4:385; PMID:25642417
103. D.M.Sansom, L.S.Walker. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006; 212:131-48; PMID:16903911; http://dx.doi.org/10.1111/j.0105-2896.2006.00419.x
104. W.A.Teft, M.G.Kirchhof, J.Madrenas. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006; 24:65-97; PMID:16551244; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090535
105. M.F.Krummel, J.P.Allison. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-65; PMID:7543139; http://dx.doi.org/10.1084/jem.182.2.459
106. O.C.Ukpo, W.L.Thorstad, J.S.Lewis, Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013; 7:113-21; PMID:23179191; http://dx.doi.org/10.1007/s12105-012-0406-z
107. S.Lyford-Pike, S.Peng, G.D.Young, J.M.Taube, W.H.Westra, B.Akpeng, T.C.Bruno, J.D.Richmon, H.Wang, J.A.Bishop, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer research 2013; 73:1733-41; PMID:23288508; http://dx.doi.org/10.1158/0008-5472.CAN-12-2384
108. B.Lu, O.J.Finn. T-cell death and cancer immune tolerance. Cell Death Differ 2008; 15:70-9; PMID:18007660; http://dx.doi.org/10.1038/sj.cdd.4402274
109. G.J.Freeman, A.J.Long, Y.Iwai, K.Bourque, T.Chernova, H.Nishimura, L.J.Fitz, N.Malenkovich, T.Okazaki, M.C.Byrne, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
110. M.J.Eppihimer, J.Gunn, G.J.Freeman, E.A.Greenfield, T.Chernova, J.Erickson, J.P.Leonard. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002; 9:133-45; PMID:11932780; http://dx.doi.org/10.1080/713774061
111. N.M.La-Beck, G.W.Jean, C.Huynh, S.K.Alzghari, D.B.Lowe. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy 2015; 35:963-76; PMID:26497482; http://dx.doi.org/10.1002/phar.1643
112. K.S.Peggs, S.A.Quezada, A.J.Korman, J.P.Allison. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18:206-13; PMID:16464564; http://dx.doi.org/10.1016/j.coi.2006.01.011
113. C.Blank, A.Mackensen. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56:739-45; PMID:17195077; http://dx.doi.org/10.1007/s00262-006-0272-1
114. S.R.Woo, M.E.Turnis, M.V.Goldberg, J.Bankoti, M.Selby, C.J.Nirschl, M.L.Bettini, D.M.Gravano, P.Vogel, C.L.Liu, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer research 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
115. K.Sakuishi, L.Apetoh, J.M.Sullivan, B.R.Blazar, V.K.Kuchroo, A.C.Anderson. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
116. J.Fourcade, Z.Sun, M.Benallaoua, P.Guillaume, I.F.Luescher, C.Sander, J.M.Kirkwood, V.Kuchroo, H.M.Zarour. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
117. R.J.Johnston, L.Comps-Agrar, J.Hackney, X.Yu, M.Huseni, Y.Yang, S.Park, V.Javinal, H.Chiu, B.Irving, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26:923-37; PMID:25465800; http://dx.doi.org/10.1016/j.ccell.2014.10.018
118. L.Derre, J.P.Rivals, C.Jandus, S.Pastor, D.Rimoldi, P.Romero, O.Michielin, D.Olive, D.E.Speiser. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010; 120:157-67; PMID:20038811; http://dx.doi.org/10.1172/JCI40070
119. V.Flacher, M.Bouschbacher, E.Verronese, C.Massacrier, V.Sisirak, O.Berthier-Vergnes, B.de Saint-Vis, C.Caux, C.Dezutter-Dambuyant, S.Lebecque, et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006; 177:7959-67; PMID:17114468; http://dx.doi.org/10.4049/jimmunol.177.11.7959
120. M.Merad, F.Ginhoux, M.Collin. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8:935-47; PMID:19029989; http://dx.doi.org/10.1038/nri2455
121. S.Domingos-Pereira, L.Decrausaz, L.Derre, M.Bobst, P.Romero, J.T.Schiller, P.Jichlinski, D.Nardelli-Haefliger. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 2013; 6:393-404; PMID:22968420; http://dx.doi.org/10.1038/mi.2012.83
122. D.M.Da Silva, A.W.Woodham, J.G.Skeate, L.K.Rijkee, J.R.Taylor, H.E.Brand, L.I.Muderspach, L.D.Roman, A.A.Yessaian, H.Q.Pham, et al. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clinical Immunology 2015; 161:197-208; PMID:26360252; http://dx.doi.org/10.1016/j.clim.2015.09.003
123. D.M.Da Silva, A.W.Woodham, L.K.Rijkee, J.G.Skeate, J.R.Taylor, M.E.Koopman, H.E.Brand, M.K.Wong, G.M.McKee, A.M.Salazar, et al. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Research 2015; 1:12-21; PMID:26665182
124. L.M.Fahey, A.B.Raff, D.M.Da Silva, W.M.Kast. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol 2009; 182:2919-28; PMID:19234187; http://dx.doi.org/10.4049/jimmunol.0803645
125. D.M.Da Silva, A.W.Woodham, P.H.Naylor, J.E.Egan, L. BN, Kast WM. Immunostimulatory activity of the cytokine-based biologic IRX-2 on human papillomavirus-exposed Langerhans cells Journal of Interferon and Cytokine Research In Press.
126. S.Kanodia, L.M.Fahey, W.M.Kast. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007; 7:79-89; PMID:17305480; http://dx.doi.org/10.2174/156800907780006869
127. G.H.Ashrafi, M.Haghshenas, B.Marchetti, M.S.Campo. E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain. Int J Cancer 2006; 119:2105-12; PMID:16823848; http://dx.doi.org/10.1002/ijc.22089
128. L.M.Fahey, A.B.Raff, D.M.Da Silva, W.M.Kast. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol 2009; 183:6151-6; PMID:19864613; http://dx.doi.org/10.4049/jimmunol.0902145
129. D.M.Da Silva, C.A.Movius, A.B.Raff, H.E.Brand, J.G.Skeate, M.K.Wong, W.M.Kast. Suppression of Langerhans cell activation is conserved amongst human papillomavirus alpha and beta genotypes, but not a micro genotype. Virology 2014; 452-453:279-86; PMID:24606705; http://dx.doi.org/10.1016/j.virol.2014.01.031
130. A.W.Woodham, A.B.Raff, L.M.Raff, D.M.Da Silva, L.Yan, J.G.Skeate, M.K.Wong, Y.G.Lin, W.M.Kast. Inhibition of Langerhans Cell Maturation by Human Papillomavirus Type 16: A Novel Role for the Annexin A2 Heterotetramer in Immune Suppression. J Immunol 2014; 192(10):4748-57; PMID:24719459
131. C.L.Trimble, R.A.Clark, C.Thoburn, N.C.Hanson, J.Tassello, D.Frosina, F.Kos, J.Teague, Y.Jiang, N.C.Barat, et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010; 185:7107-14; PMID:21037100; http://dx.doi.org/10.4049/jimmunol.1002756
132. W.Yang, Y.Song, Y.L.Lu, J.Z.Sun, H.W.Wang. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 2013; 139:513-22; PMID:23521696; http://dx.doi.org/10.1111/imm.12101
133. A.G.Bais, I.Beckmann, J.Lindemans, P.C.Ewing, C.J.Meijer, P.J.Snijders, T.J.Helmerhorst. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005; 58:1096-100; PMID:16189158; http://dx.doi.org/10.1136/jcp.2004.025072
134. B.C.Peghini, D.R.Abdalla, A.C.Barcelos, L.Teodoro, E.F.Murta, M.A.Michelin. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol 2012; 73:920-6; PMID:22749886; http://dx.doi.org/10.1016/j.humimm.2012.06.003
135. M.E.Scott, Y.B.Shvetsov, P.J.Thompson, B.Y.Hernandez, X.Zhu, L.R.Wilkens, J.Killeen, D.D.Vo, A.B.Moscicki, M.T.Goodman. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer 2013; 133:1187-96; PMID:23436563; http://dx.doi.org/10.1002/ijc.28119
136. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang, M.Burow, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093
137. E.Lukesova, J.Boucek, E.Rotnaglova, M.Salakova, E.Koslabova, M.Grega, T.Eckschlager, B.Rihova, B.Prochazka, J.Klozar, et al. High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. Biomed Res Int 2014; 2014:303929; PMID:24864233; http://dx.doi.org/10.1155/2014/303929
138. S.Nagaraj, K.Gupta, V.Pisarev, L.Kinarsky, S.Sherman, L.Kang, D.L.Herber, J.Schneck, D.I.Gabrilovich. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609
139. S.C.Stone, R.A.Rossetti, A.M.Lima, A.P.Lepique. HPV associated tumor cells control tumor microenvironment and leukocytosis in experimental models. Immun Inflamm Dis 2014; 2:63-75; PMID:25400927; http://dx.doi.org/10.1002/iid3.21
140. F.Y.Yue, R.Dummer, R.Geertsen, G.Hofbauer, E.Laine, S.Manolio, G.Burg. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71:630-7; PMID:9178819; http://dx.doi.org/10.1002/(SICI)1097-0215(19970516)71:4%3c630::AID-IJC20%3e3.0.CO;2-E
141. A.Bolpetti, J.S.Silva, L.L.Villa, A.P.Lepique. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27; PMID:20525400; http://dx.doi.org/10.1186/1471-2172-11-27
142. J.M.Alcocer-Gonzalez, J.Berumen, R.Tamez-Guerra, V.Bermudez-Morales, O.Peralta-Zaragoza, R.Hernandez-Pando, J.Moreno, P.Gariglio, V.Madrid-Marina. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006; 19:481-91; PMID:16987066; http://dx.doi.org/10.1089/vim.2006.19.481
143. J.C.Steele, C.H.Mann, S.Rookes, T.Rollason, D.Murphy, M.G.Freeth, P.H.Gallimore, S.Roberts. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005; 93:248-59; PMID:15986031; http://dx.doi.org/10.1038/sj.bjc.6602679
144. C.L.Trimble, S.Peng, C.Thoburn, F.Kos, T.C.Wu. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother 2010; 59:799-803; PMID:20012604; http://dx.doi.org/10.1007/s00262-009-0806-4
145. S.Stevanovic, L.M.Draper, M.M.Langhan, T.E.Campbell, M.L.Kwong, J.R.Wunderlich, M.E.Dudley, J.C.Yang, R.M.Sherry, U.S.Kammula, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015; 33:1543-50; PMID:25823737; http://dx.doi.org/10.1200/JCO.2014.58.9093
146. H.Khallouf, A.K.Grabowska, A.B.Riemer. Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) 2014; 2:422-62; PMID:26344626; http://dx.doi.org/10.3390/vaccines2020422
147. C.M.Corona Gutierrez, A.Tinoco, T.Navarro, M.L.Contreras, R.R.Cortes, P.Calzado, L.Reyes, R.Posternak, G.Morosoli, M.L.Verde, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15:421-31; PMID:15144573; http://dx.doi.org/10.1089/10430340460745757